Abstract titles reveal some of ASCO’s key datasets.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.

The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.